First Tracks Biotherapeutics Inc
NASDAQ:TRAXBiotechnology
-$0.89 today
- Market cap
- $1.87B
- Beta
- 0.00
- P/E (TTM)
- -6.1
- EPS (TTM)
- -$2.81
Volume 0.75M
Average 0.43M
TRAX Total Current Liabilities
All obligations due within one year.
First Tracks Biotherapeutics IncNASDAQ: TRAX
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities remains negative
Q1 FY2026 total current liabilities was $33.11M, compared with $0 a year earlier.
Context
- Total current liabilities amounted to 11.4% of total assets at the end of Q1 FY2026.
- Total current liabilities increased in 1 of the last 2 fiscal years.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 31.02M USD
- Year-over-year change
- -14.3%
- 2-year CAGR
- +30.5%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 31.02M | -14.3% |
| FY2024 | 2024-12-31 | 36.18M | +98.6% |
| FY2023 | 2023-12-31 | 18.22M | — |
Total Current Liabilities vs competitors
How TRAX compares with its peers on the latest reported figures
- TRAX's Mar 2026 total current liabilities of $33.11M is the 5th highest of the 10 companies compared; the peer median is $27.37M.
- Total current liabilities amounts to 11.4% of total assets for TRAX, versus a peer median of 11.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $104.02M | +64.5% | +34.1% | 13.7% | |
| Mar 2026 | $46.11M | +92.3% | +81.0% | 11.5% | |
| Mar 2026 | $41.7M | -5.3% | +14.0% | 12.6% | |
| Mar 2026 | $38.36M | +49.9% | +32.8% | 20.2% | |
TRAXFirst Tracks Biotherapeutics Inc | Mar 2026 | $33.11M | — | — | 11.4% |
| Mar 2026 | $27.37M | +27.2% | +9.3% | 13.8% | |
| Mar 2026 | $13.46M | +46.5% | +41.5% | 9.2% | |
| Jun 2026 | $12.62M | — | — | 9.8% | |
| Jun 2026 | $11.71M | +9.6% | -10.7% | 4.9% | |
CLYMClimb Bio, Inc. | Mar 2026 | $4.07M | -42.1% | +4.6% | 2.7% |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding TRAX) | $27.37M | +36.9% | +23.4% | 11.5% | |
Competitors are the stored peer set for TRAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
First Tracks Biotherapeutics Inc
NASDAQ:TRAX
Intrinsic Alpha fair value
Locked
Current Price
$44.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.